ArticlePloS one2026
A pumpless liver-adipose model for studying metabolic dysfunction and drug responses.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic dysfunction is a primary driver of chronic diseases, such as obesity and type 2 diabetes. Developing in vitro models allows to understand metabolic mechanisms and develop effective treatments. To this end, a pumpless open-top co-culture (POCC) device to simulate liver-adipose tissue interactions was developed. The POCC comprises a four-chamber bioreactor with an open-top configuration and an easy-to-assemble cover cap. Rotational motion enabled perfusion of culture media among the interconnected chambers. HepG2 and 3T3-L1 cells were co-cultured and exposed to olanzapine (Olz), chlorogenic acid (CGA), and metformin (Met) for four days. Drug responses in the POCC were compared with those in 96-well monocultures. Assessments were conducted for glucose/triglyceride (TG) levels, lipid accumulation, and cell viability. While viability remained unchanged, Olz increased lipid content, extracellular glucose and TG levels in the POCC model, effects that CGA and Met mitigated. This practical and physiologically relevant platform offers a promising alternative for preclinical screenings that could be employed to study other multi-tissue interactions in various disease models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.